Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2    symbols : ALLK    save search
Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases
Published: 2021-12-22 (Crawled : 01:00) - globenewswire.com
ALLK | $1.065 0.47% 0.47% 420K twitter stocktwits trandingview |
Health Technology
 | | O: -87.46% H: 2.55% C: -19.19%
phase 2 phase 2/3 gastrointestinal disease test topline phase 3
Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 Eosinophilic Esophagitis Clinical Trials of Lirentelimab (AK002)
Published: 2021-06-07 (Crawled : 18:00) - biospace.com/
ALLK | $1.065 0.47% 0.47% 420K twitter stocktwits trandingview |
Health Technology
 | | O: -0.12% H: 4.21% C: 2.01%
phase 2 clinical trials phase 2/3 phase 3 trial enroll
Gainers vs Losers
67% 33%

Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.